Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Topical PF-07295324 and PF-07259955 in Healthy Adults
NCT05206604Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing PF-07295324 with PF-07259955 (2 arms). Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Laboratory Abnormalities at Day 12 and 3 more. Started Feb 2022; status: completed.
02
Drugs
PF-07295324PF-07259955
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05206604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206604.